GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (NAS:ALDX) » Definitions » PB Ratio

Aldeyra Therapeutics (Aldeyra Therapeutics) PB Ratio : 1.97 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aldeyra Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), Aldeyra Therapeutics's share price is $3.77. Aldeyra Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $1.91. Hence, Aldeyra Therapeutics's PB Ratio of today is 1.97.

The historical rank and industry rank for Aldeyra Therapeutics's PB Ratio or its related term are showing as below:

ALDX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 8.4
Current: 1.97

During the past 13 years, Aldeyra Therapeutics's highest PB Ratio was 8.40. The lowest was 0.00. And the median was 0.00.

ALDX's PB Ratio is ranked better than
59.34% of 1311 companies
in the Biotechnology industry
Industry Median: 2.5 vs ALDX: 1.97

During the past 12 months, Aldeyra Therapeutics's average Book Value Per Share Growth Rate was -18.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 9.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -0.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Aldeyra Therapeutics was 22.40% per year. The lowest was -9.40% per year. And the median was 8.80% per year.

Back to Basics: PB Ratio


Aldeyra Therapeutics PB Ratio Historical Data

The historical data trend for Aldeyra Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics PB Ratio Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.46 4.46 1.13 2.70 1.73

Aldeyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 3.80 3.21 1.73 1.71

Competitive Comparison of Aldeyra Therapeutics's PB Ratio

For the Biotechnology subindustry, Aldeyra Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's PB Ratio falls into.



Aldeyra Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Aldeyra Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=3.77/1.909
=1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Aldeyra Therapeutics  (NAS:ALDX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Aldeyra Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd C Brady director, officer: President and CEO C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Martin Joseph Joyce director 1050 HINGHAM STREET, ROCKLAND MA 02370
Bruce Greenberg officer: See Remarks C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Stephen Machatha officer: Chief Development Officer 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Richard Douglas director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Ben Bronstein director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David J Clark officer: Chief Medical Officer 131 HARTWELL AVE, LEXINGTON MA 02421
David Mcmullin officer: SVP Corp. Dev. & Strategy C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joshua Reed officer: Chief Financial Officer C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Jesse I Treu director, 10 percent owner
Stephen J Tulipano officer: Chief Financial Officer C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140

Aldeyra Therapeutics (Aldeyra Therapeutics) Headlines

From GuruFocus